Enliven Therapeutics Inc (ELVN)

Currency in USD
58.780
-0.640(-1.08%)
Closed·
57.400-1.380(-2.35%)
·
ELVN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
57.39059.270
52 wk Range
14.78562.320
Key Statistics
Prev. Close
58.78
Open
59.25
Day's Range
57.39-59.27
52 wk Range
14.785-62.32
Volume
1.28M
Average Volume (3m)
1.42M
1-Year Change
211.1699%
Book Value / Share
12.82
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ELVN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
72.222
Upside
+22.87%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings downwards for the upcoming period

Enliven Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy

Analyst Ratings

10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 72.222
(+22.87% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Baird
Buy75.00+27.59%60.00MaintainAug 06, 2026
Stifel
Buy82.00+39.50%80.00MaintainAug 06, 2026
Guggenheim
Buy78.00+32.70%80.00MaintainAug 06, 2026
Goldman Sachs
Buy80.00+36.10%67.00MaintainAug 06, 2026
Goldman Sachs
Buy67.00+13.98%59.00MaintainJul 21, 2026

Earnings

Latest Release
Aug 05, 2026
EPS / Forecast
-0.49 / -0.39
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ELVN Income Statement

Compare ELVN to Peers and Sector

Metrics to compare
ELVN
Peers
Sector
Relationship
P/E Ratio
−40.7x−0.9x−0.4x
PEG Ratio
−2.47−0.120.00
Price/Book
4.8x2.4x2.6x
Price / LTM Sales
-2.4x3.1x
Upside (Analyst Target)
19.1%53.3%47.5%
Fair Value Upside
Unlock−0.6%5.9%Unlock

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
23.22M33.26%1.38B
Other Institutional Investors
55.29M66.74%3.29B
Public Companies & Retail Investors
0.000.00%0.00
Total
78.51M100.00%4.67B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
FMR LLC15.34%10,713,536636,598
OrbiMed Advisors LLC9.70%6,774,507402,541

People Also Watch

26.34
TNGX
-4.81%
30.29
VERA
-4.08%
108.49
DNTH
-2.96%
18.310
ERAS
+1.05%
109.62
KYMR
+0.96%

FAQ

What Is the Enliven Therapeutics (ELVN) Stock Price Today?

The Enliven Therapeutics stock price today is 58.780 USD.

What Stock Exchange Does Enliven Therapeutics Trade On?

Enliven Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Enliven Therapeutics?

The stock symbol for Enliven Therapeutics is "ELVN."

What Is the Enliven Therapeutics Market Cap?

As of today, Enliven Therapeutics market cap is 4.310B USD.

What Is Enliven Therapeutics's Earnings Per Share (TTM)?

The Enliven Therapeutics EPS (TTM) is -1.672.

When Is the Next Enliven Therapeutics Earnings Date?

Enliven Therapeutics will release its next earnings report on Nov 18, 2026.

From a Technical Analysis Perspective, Is ELVN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Enliven Therapeutics Stock Split?

Enliven Therapeutics has split 1 times.

How Many Employees Does Enliven Therapeutics Have?

Enliven Therapeutics has 67 employees.

What is the current trading status of Enliven Therapeutics (ELVN)?

As of Aug 12, 2026, Enliven Therapeutics (ELVN) is trading at a price of 58.780 USD, with a previous close of 58.780 USD. The stock has fluctuated within a day range of 57.390 USD to 59.270 USD, while its 52-week range spans from 14.785 USD to 62.320 USD.

What Is Enliven Therapeutics (ELVN) Price Target According to Analysts?

The average 12-month price target for Enliven Therapeutics is 72.222 USD, with a high estimate of 82 USD and a low estimate of 62 USD. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +22.87% Upside potential.

What Is the ELVN Premarket Price?

ELVN's last pre-market stock price is 59.900 USD. The pre-market share volume is 500.000, and the stock has decreased by 0.480, or 0.810%.

What Is the ELVN After Hours Price?

ELVN's last after hours stock price is 57.400 USD, the stock has decreased by -1.380, or -2.350%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.